Effects of interferon plus ribavirin treatment on NF-κB, TGF-β1, and metalloproteinase activity in chronic hepatitis C

[1]  D. Brenner,et al.  Erratum: Liver fibrosis (Journal of Clinical Investigation (2005) 115 (209-218) DOI:10.1172/JCI200524282) , 2005 .

[2]  G. Fattovich,et al.  A randomized trial of prolonged high dose of interferon plus ribavirin for hepatitis C patients nonresponders to interferon alone , 2004, Journal of viral hepatitis.

[3]  L. Boscá,et al.  Increased intrahepatic cyclooxygenase 2, matrix metalloproteinase 2, and matrix metalloproteinase 9 expression is associated with progressive liver disease in chronic hepatitis C virus infection: role of viral core and NS5A proteins , 2004, Gut.

[4]  F. Ramires,et al.  Activation of nuclear factor-kappaB and its proinflammatory mediator cascade in the infarcted rat heart. , 2004, Biochemical and biophysical research communications.

[5]  M. Pinzani,et al.  Liver fibrosis: from the bench to clinical targets. , 2004, Digestive and Liver Disease.

[6]  L. Seeff,et al.  Aasld Practice Guideline Diagnosis, Management, and Treatment of Hepatitis C , 2003 .

[7]  P. Marcellin,et al.  Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. , 2004, Annals of internal medicine.

[8]  F. Morel,et al.  Circulating Matrix Metalloproteinases 1, 2, 9 and Their Inhibitors TIMP-1 and TIMP-2 as Serum Markers of Liver Fibrosis in Patients With Chronic Hepatitis C: Comparison With PIIINP and Hyaluronic Acid , 2004, American Journal of Gastroenterology.

[9]  P. Marcellin,et al.  Effect of peginterferon alfa‐2a on liver histology in chronic hepatitis C: A meta‐analysis of individual patient data , 2004, Hepatology.

[10]  G. Fattovich,et al.  A randomized trial of consensus interferon in combination with ribavirin as initial treatment for chronic hepatitis C. , 2003, Journal of hepatology.

[11]  G. Leandro,et al.  Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. , 2003, Journal of hepatology.

[12]  Ivan Stamenkovic,et al.  Extracellular matrix remodelling: the role of matrix metalloproteinases , 2003, The Journal of pathology.

[13]  D. Schuppan,et al.  Hepatitis C and liver fibrosis , 2003, Cell Death and Differentiation.

[14]  G. Fattovich,et al.  Efficacy of prolonged 5 million units of interferon in combination with ribavirin for relapser patients with chronic hepatitis C , 2003, Journal of viral hepatitis.

[15]  L. Seeff,et al.  Natural history of chronic hepatitis C , 2002, Hepatology.

[16]  E. Petinaki,et al.  Matrix metalloproteinases and their inhibitors in acute viral hepatitis , 2002, Journal of viral hepatitis.

[17]  M. Manns,et al.  Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. , 2002, Gastroenterology.

[18]  S. Dooley,et al.  Roles of TGF-beta in hepatic fibrosis. , 2002, Frontiers in bioscience : a journal and virtual library.

[19]  T. Lawrence,et al.  Possible new role for NF-κB in the resolution of inflammation , 2001, Nature Medicine.

[20]  P. Boya,et al.  Nuclear factor‐κB in the liver of patients with chronic hepatitis C: Decreased RelA expression is associated with enhanced fibrosis progression , 2001, Hepatology.

[21]  P. Schirmacher,et al.  Prediction of progressive liver fibrosis in hepatitis C infection by serum and tissue levels of transforming growth factor‐β , 2001, Journal of viral hepatitis.

[22]  Kenneth Koury,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[23]  F. Marra,et al.  Cytokine Receptors and Signaling in Hepatic Stellate Cells , 2001, Seminars in liver disease.

[24]  S. Orenstein,et al.  The effects of increassing doses of ranitidine on intragastric pH in children , 2001 .

[25]  M. Manns,et al.  Matrix metalloproteinase (MMP)-2, MMP-7, and tissue inhibitor of metalloproteinase-1 are closely related to the fibroproliferative process in the liver during chronic hepatitis C. , 2001, Journal of hepatology.

[26]  M. Cybulsky,et al.  NF-κB: pivotal mediator or innocent bystander in atherogenesis? , 2001 .

[27]  U. Andersson,et al.  In situ expression of transforming growth factor-beta1-3, latent transforming growth factor-beta binding protein and tumor necrosis factor-alpha in liver tissue from patients with chronic hepatitis C. , 2000, Scandinavian journal of gastroenterology.

[28]  G. Davis,et al.  Impact of interferon alfa‐2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C , 2000, Hepatology.

[29]  R. Schmid,et al.  NF-κB/Rel/IκB: Implications in gastrointestinal diseases , 2000 .

[30]  H. Lodish,et al.  Role of transforming growth factor beta in human disease. , 2000, The New England journal of medicine.

[31]  R. Wiesner,et al.  Intragraft localization of activated nuclear factor κB in recurrent hepatitis C virus disease following liver transplantation , 2000, Hepatology.

[32]  M. Sata,et al.  Histologic Improvement of Fibrosis in Patients with Hepatitis C Who Have Sustained Response to Interferon Therapy , 2000, Annals of Internal Medicine.

[33]  D. Rockey.  Hepatic fibrogenesis and hepatitis C. , 2000, Seminars in gastrointestinal disease.

[34]  Y. Liaw,et al.  Activation of nuclear factor κB in hepatitis C virus infection: Implications for pathogenesis and hepatocarcinogenesis , 2000, Hepatology.

[35]  T. Yen.  Nuclear factor κB and hepatitis C—is there a connection? , 2000 .

[36]  S. Friedman.  Molecular Regulation of Hepatic Fibrosis, an Integrated Cellular Response to Tissue Injury* , 2000, The Journal of Biological Chemistry.

[37]  M. Rojkind.  Role of metalloproteinases in liver fibrosis. , 1999, Alcoholism, clinical and experimental research.

[38]  K. Okita,et al.  Quantitative analysis of liver fibrosis and stellate cell changes in patients with chronic hepatitis C after interferon therapy , 1999, American Journal of Gastroenterology.

[39]  M. Vidaud,et al.  Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc Group. , 1999, Gastroenterology.

[40]  H. T. Head,et al.  Global surveillance and control of hepatitis C , 1999 .

[41]  A. Bhalla,et al.  Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. , 1997, Gastroenterology.

[42]  G. Davis,et al.  Transforming growth factor‐ß1 in chronic hepatitis C , 1997 .

[43]  M. Rugge,et al.  Liver stellate cells in chronic viral hepatitis: the effect of interferon therapy. , 1996, Journal of hepatology.

[44]  J. Iredale,et al.  Expression of tissue inhibitor of metalloproteinases 1 and 2 is increased in fibrotic human liver. , 1996, Gastroenterology.

[45]  K. Ishak,et al.  Histological grading and staging of chronic hepatitis. , 1995 .

[46]  R. Benarous,et al.  Quantitative analysis of transforming growth factor β1 messenger RNA in the liver of patients with chronic hepatitis C: Absence of correlation between high levels and severity of disease , 1995, Hepatology.

[47]  T. Lawrence,et al.  Possible new role for NF-kappaB in the resolution of inflammation. , 2001, Nature medicine.

[48]  M. Cybulsky,et al.  NF-kappaB: pivotal mediator or innocent bystander in atherogenesis? , 2001, The Journal of clinical investigation.

[49]  A. Baldwin.  Series introduction: the transcription factor NF-kappaB and human disease. , 2001, The Journal of clinical investigation.

[50]  B. Bacon,et al.  Hepatic alpha-smooth muscle actin expression in hepatitis C patients before and after interferon therapy. , 2001, Hepato-gastroenterology.

[51]  A. Baldwin.  Series Introduction: The transcription factor NF-κB and human disease , 2001 .

[52]  R. Schmid,et al.  NF-kappaB/rel/IkappaB: implications in gastrointestinal diseases. , 2000, Gastroenterology.

[53]  T. Yen.  Nuclear factor kappaB and hepatitis C--Is there a connection? , 2000, Hepatology.

[54]  Y. Matsuzawa,et al.  Reduced plasma transforming growth factor-beta1 levels in patients with chronic hepatitis C after interferon-alpha therapy: association with regression of hepatic fibrosis. , 1999, Journal of hepatology.

[55]  D. Lavanchy,et al.  Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. , 1999, Journal of viral hepatitis.

[56]  G. Davis,et al.  Transforming growth factor-beta 1 in chronic hepatitis C. , 1997, Journal of viral hepatitis.